BIIB - BIOGEN INC.

184.02
-4.030   -2.190%

Share volume: 1,049,589
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$188.05
-4.03
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
69%
Profitability 84%
Dept financing 43%
Liquidity 29%
Performance 70%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.07%
1 Month
-0.77%
3 Months
1.12%
6 Months
31.50%
1 Year
29.00%
2 Year
-16.74%
Key data
Stock price
$184.02
P/E Ratio 
19.97
DAY RANGE
$181.79 - $187.05
EPS 
$8.83
52 WEEK RANGE
$110.04 - $202.41
52 WEEK CHANGE
$28.00
MARKET CAP 
25.818 B
YIELD 
N/A
SHARES OUTSTANDING 
146.759 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
0.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$952,793
AVERAGE 30 VOLUME 
$1,397,339
Company detail
CEO: Christopher A. Viehbacher
Region: US
Website: biogen.com
Employees: 8,720
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. It also offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and pemphigus vulgaris.

Recent news